CORT
- Corcept Therapeutics Incorporated
()
Overview
Company Summary
Corcept Therapeutics Incorporated (CORT) is a pharmaceutical company that focuses on the development and commercialization of medications for severe metabolic, oncologic, and psychiatric disorders. The company's primary therapeutic area of expertise lies in the field of cortisol modulators.
Corcept specializes in the research, development, and commercialization of drugs that target cortisol, a hormone produced by the adrenal glands. Cortisol plays a crucial role in regulating a wide range of physiological and metabolic processes within the body. However, excessive cortisol levels or improper cortisol regulation can lead to various health problems.
One of Corcept's main medications is Korlym (mifepristone), which is the first and only FDA-approved medication for the treatment of hyperglycemia in patients with endogenous Cushing's syndrome. Endogenous Cushing's syndrome is a rare hormonal disorder caused by excess cortisol production within the body. Korlym works by blocking the action of cortisol receptors, thereby reducing the symptoms associated with the disorder.
Corcept is also involved in the development of other cortisol modulators, such as relacorilant (formerly CORT125134), which is being evaluated for its potential in several oncologic and psychiatric conditions, including prostate cancer and major depressive disorder.
In addition to their focus on developing innovative therapies, Corcept Therapeutics actively engages in clinical research, regulatory affairs, and commercialization efforts to bring their medications to high-need patient populations. Their ultimate goal is to improve the quality of life for patients suffering from severe metabolic, oncologic, and psychiatric disorders by addressing the dysregulation of cortisol levels and related mechanisms.